What is the latest market price of roselixizumab?
Rozanolixizumab (Rozanolixizumab) is a monoclonal antibody drug with a unique mechanism. Its target is the neonatal Fc receptor (FcRn). This target is primarily responsible for recycling and protecting IgG antibodies in the body, preventing them from being rapidly cleared by the kidneys and liver. Rozelixizumab competes with FcRn to block IgG recycling, thereby rapidly reducing the level of pathogenic IgG antibodies in the body and improving chronic autoimmune diseases mediated by it.

At present, roselixizumab is mainly suitable for the treatment of anti-acetylcholine receptor antibody-positive myasthenia gravis (AChR-Ab+ gMG; rare disease), which is a chronic and progressive autoimmune neuromuscular disease with clinical manifestations of muscle weakness, eyelid ptosis, dysphagia and even respiratory failure. In clinical studies, the drug has shown rapid onset of action and good safety, providing patients with new treatment possibilities.
Regarding the market price, according to public channel data, the price of roselixizumab when it was launched in the United States was 280 mg/2mL per box, with a price of more than 6,000 US dollars. If calculated based on one injection per week and a course of treatment lasting 8-12 weeks, the total treatment cost is extremely expensive. In other regions, such as the European Union and Japan, the drug also maintains high sales prices and is a typical high-end innovative drug. It is worth noting that there are currently no generic drugs on the market, so the market price is unlikely to drop significantly in the short term.
In the Chinese market, roselixizumab has not yet been officially commercialized, so there is no public retail price. Some cross-border drug platforms or medical service institutions may be able to assist patients in purchasing original drugs from overseas, but due to international logistics, customs restrictions and exchange rate fluctuations, the final price may vary greatly. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.
Reference materials:https://www.drugs.com/rystiggo.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)